#ZW209

25 Oct 2026

Roche licenses lung cancer drug ZW209 from Zymeworks

Roche gains exclusive global rights to the DLL3-targeting T-cell engager ZW209 from Vancouver-based Zymeworks, with up to $758 million in conditional payments.

Read more